The inhibition of NLRP3, a critical component of the innate immune system known to drive steroid‐resistant neutrophilic inflammation in severe asthma, positions BBR as a potential agent for managing difficult‐to‐treat asthma phenotypes. Here, NLRP3 is linked to asthma.